At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 130 enrolled
Drug / intervention
DE-114 ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term Open-label Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3 -
In Brief
A Phase 3 clinical trial evaluating DE-114 ophthalmic solution for Allergic Conjunctivitis. Completed, enrolled 130 participants across 1 site.
Detailed Summary
Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedJun 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Posted 15.1 years ago
Interventions
DE-114 ophthalmic solutiondrug